Europe Idiopathic Pulmonary Fibrosis Treatment Market Size, Report 2023-2028

Europe Idiopathic Pulmonary Fibrosis Treatment Market: Industry Trends, Share, Size, Growth, Opportunity and Forecast 2023-2028

Report Format: PDF+Excel | Report ID: SR112023A5508

Year End sale Buy Now

Market Overview:

The Europe idiopathic pulmonary fibrosis treatment market size reached US$ 553 Million in 2022. Looking forward, IMARC Group expects the market to reach US$ 892 Million by 2028, exhibiting a growth rate (CAGR) of 8.3% during 2023-2028.

Idiopathic pulmonary fibrosis (IPF) is a persistent lung infection that causes scarring of the lungs. This hampers the oxygen-carrying functionality of the organ, thereby resulting in breathing difficulties. Some of the common symptoms include a persistent dry cough, fatigue, loss of appetite, and swollen limbs. IPF is diagnosed through blood tests, chest X-ray, computer tomography (CT) scan, lung biopsy, and pulmonary function tests. It can be treated by prescribing anti-fibrotic drugs and supportive treatment options, such as oxygen therapy and palliative care.

Note: Information in the above chart consists of dummy data and is only shown here for representation purpose. Kindly contact us for the actual market size and trends.

To get more information about this market, Request Sample

Europe Idiopathic Pulmonary Fibrosis Treatment Market Trends:

The Europe IPF treatment market is primarily being driven by the increasing prevalence of chronic lung and fibrotic diseases, especially in the geriatric population. This can be attributed to changing living standards, high smoking rates, and increasing environment pollutants. Other than this, increasing health consciousness amongst consumers and rising awareness regarding the presence of effective IPF preventive and management strategies are catalyzing the market growth. In line with this, increasing government expenditures for the development of existing healthcare systems and rapid advancements in diagnostic techniques are acting as another growth-inducing factor. The implementation of favorable regulatory policies and continuous investments in research and development (R&D) activities for introducing novel medicines are further creating a positive outlook for the market in the region.

Key Market Segmentation:

IMARC Group provides an analysis of the key trends in each sub-segment of the Europe idiopathic pulmonary fibrosis treatment market report, along with forecasts at the regional and country level from 2023-2028. Our report has categorized the market based on drug class and end user.

Breakup by Drug Class:

Note: Information in the above chart consists of dummy data and is only shown here for representation purpose. Kindly contact us for the actual market size and trends.

To get more information about this market, Request Sample

MAPK Inhibitors
Tyrosine Inhibitors
Autotaxin Inhibitors

Breakup by End User:

Hospitals
Long-term Care Facilities
Others

Breakup by Country:

Germany
France
United Kingdom
Italy
Spain
Others

Competitive Landscape:

The competitive landscape of the industry has also been examined along with the profiles of the key players.

Report Coverage:

Report Features	Details
Base Year of the Analysis	2022
Historical Period	2017-2022
Forecast Period	2023-2028
Units	US$ Million
Segment Coverage	Drug Class, End User, Country
Countries Covered	Germany, France, United Kingdom, Italy, Spain, Others
Customization Scope	10% Free Customization
Report Price and Purchase Option	Single User License: US$ 2699 Five User License: US$ 3699 Corporate License: US$ 4699
Post-Sale Analyst Support	10-12 Weeks
Delivery Format	PDF and Excel through Email (We can also provide the editable version of the report in PPT/Word format on special request)

Key Questions Answered in This Report

The Europe idiopathic pulmonary fibrosis treatment market was valued at US$ 553 Million in 2022.

We expect the Europe idiopathic pulmonary fibrosis treatment market to exhibit a CAGR of 8.3% during 2023-2028.

The rising prevalence of chronic lung and fibrotic diseases, along with the growing consumer awareness regarding the presence of effective idiopathic pulmonary fibrosis preventive and management treatment, is primarily driving the Europe idiopathic pulmonary fibrosis treatment market.

The sudden outbreak of the COVID-19 pandemic had led to the postponement of elective idiopathic pulmonary fibrosis treatment procedures to reduce the risk of the coronavirus infection upon hospital visits and interaction with healthcare professionals or medical equipment.

Based on the drug class, the Europe idiopathic pulmonary fibrosis treatment market has been bifurcated into MAPK inhibitors, tyrosine inhibitors, and autotaxin inhibitors. Among these, tyrosine inhibitors currently hold the majority of the total market share.

Based on the end user, the Europe idiopathic pulmonary fibrosis treatment market can be segmented into hospitals, long-term care facilities, and others. Currently, hospitals exhibit a clear dominance in the market.

On a regional level, the market has been classified into Germany, France, United Kingdom, Italy, Spain, and others.

Need more help?

Speak to our experienced analysts for insights on the current market scenarios.
Include additional segments and countries to customize the report as per your requirement.
Gain an unparalleled competitive advantage in your domain by understanding how to utilize the report and positively impacting your operations and revenue.
For further assistance, please connect with our analysts.

Purchase options Year End sale

Single User License ~~$2699~~ $2429
Five User License ~~$3699~~ $3144
Corporate License ~~$4699~~ $3759

Inquire Before Buying

Speak to an Analyst

Request Brochure

Request Customization

Benefits of Customization

Personalize this research

Triangulate with your data

Get data as per your format and definition

Gain a deeper dive into a specific application, geography, customer, or competitor

Any level of personalization

Get in Touch With Us

UNITED STATES

Phone: +1-631-791-1145

INDIA

Phone: +91-120-433-0800

UNITED KINGDOM

Phone: +44-753-713-2163

Email: sales@imarcgroup.com

Client Testimonials

IMARC made the whole process easy. Everyone I spoke with via email was polite, easy to deal with, kept their promises regarding delivery timelines and were solutions focused. From my first contact, I was grateful for the professionalism shown by the whole IMARC team. I recommend IMARC to all that need timely, affordable information and advice. My experience with IMARC was excellent and I can not fault it.

The IMARC team was very reactive and flexible with regard to our requests. A very good overall experience. We are happy with the work that IMARC has provided, very complete and detailed. It has contributed to our business needs and provided the market visibility that we required

We were very happy with the collaboration between IMARC and Colruyt. Not only were your prices competitive, IMARC was also pretty fast in understanding the scope and our needs for this project. Even though it was not an easy task, performing a market research during the COVID-19 pandemic, you were able to get us the necessary information we needed. The IMARC team was very easy to work with and they showed us that it would go the extra mile if we needed anything extra

Last project executed by your team was as per our expectations. We also would like to associate for more assignments this year. Kudos to your team.

We would be happy to reach out to IMARC again, if we need Market Research/Consulting/Consumer Research or any associated service. Overall experience was good, and the data points were quite helpful.

Arabian Plastic Manufacturing Company Ltd.

The figures of market study were very close to our assumed figures. The presentation of the study was neat and easy to analyse. The requested details of the study were fulfilled. My overall experience with the IMARC Team was satisfactory.

The overall cost of the services were within our expectations. I was happy to have good communications in a timely manner. It was a great and quick way to have the information I needed.

My questions and concerns were answered in a satisfied way. The costs of the services were within our expectations. My overall experience with the IMARC Team was very good.

I agree the report was timely delivered, meeting the key objectives of the engagement. We had some discussion on the contents, adjustments were made fast and accurate. The response time was minimum in each case. Very good. You have a satisfied customer.

We would be happy to reach out to IMARC for more market reports in the future. The response from the account sales manager was very good. I appreciate the timely follow ups and post purchase support from the team. My overall experience with IMARC was good.

IMARC was a good solution for the data points that we really needed and couldn't find elsewhere. The team was easy to work, quick to respond, and flexible to our customization requests.